SCHEMBL7031388

SCHEMBL7031388

COc1cc([C@@H](C)OC(=O)O[C@H]2C[C@H](n3cc(C)c(=O)[nH]c3=O)O[C@@H]2CO)c([N+](=O)[O-])cc1OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
RNASE1 P07998 1/20 0.52
TK1 P04183 4/20 0.43
TK2 O00142 4/20 0.43
TOP2A P11388 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7031391 1.00 RNASE1 (0.52) RNASE1TK1TK2TOP2A
SCHEMBL7034889 0.92 RNASE1 (0.53) RNASE1TK1TK2TOP2A
SCHEMBL7034888 0.92 RNASE1 (0.53) RNASE1TK1TK2TOP2A
SCHEMBL7035273 0.91 TOP2A (0.51) RNASE1TK1TK2TOP2A
SCHEMBL7038044 0.83 RNASE1 (0.53) RNASE1TK1TK2
SCHEMBL7101354 0.82 KDM4E (0.53) RNASE1
SCHEMBL7105462 0.81 POLB (0.56) RNASE1
SCHEMBL6892320 0.80 RNASE1 (0.56) RNASE1TK1TK2TOP2A
SCHEMBL6892317 0.80 RNASE1 (0.54) RNASE1TK1TK2TOP2A
SCHEMBL7039861 0.78 SLC29A1 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030013868-A1 C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support LINDEN TECHNOLOGIES, INC., A DELAWARE CORPORATION 2003-01-16 US disclosed
US-20030009027-A1 C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support LINDEN TECHNOLOGIES, INC., A DELAWARE CORPORATION 2003-01-09 US disclosed
US-6489466-B2 PRODUCING IMMOBILIZED OLIGONUCLEOTIDES ON A SUBSTRATE BY COVALENTLY ATTACHING A FIRST NUCLEOTIDE OR OLIGONUCLEOTIDE VIA A C-5' OXYGEN OF THE NUCLEOTIDE TO THE SUBSTRATE; C-3'OXYGEN PROTECTED WITH PHOTO- OR CHEMICAL-LABILE GROUPS LINDEN TECHNOLOGIES, INC. 2002-12-03 US disclosed
US-20010044530-A1 C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support LINDEN TECHNOLOGIES, INC. 2001-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013868-A1 C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support RNGTT, BCDIN3D, NT5C3B RNASE1 165/4885TK1 371/4885TK2 1093/4885
US-20010044530-A1 C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support RNGTT, BCDIN3D, NT5C3B RNASE1 165/4885TK1 371/4885TK2 1093/4885
US-20030009027-A1 C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support RNGTT, BCDIN3D, NT5C3B RNASE1 165/4885TK1 371/4885TK2 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.